Description
The **OTTAVA™ Robotic Surgical System**, developed by **Johnson & Johnson MedTech**, represents a new generation of robotic-assisted surgery designed to enhance precision, efficiency, and flexibility in minimally invasive procedures. Unlike conventional robotic platforms, OTTAVA features a revolutionary **table-integrated architecture**, with four low-profile robotic arms that remain hidden beneath the operating table when not in use. This innovative design significantly reduces the system's operating room footprint while improving workflow and providing greater access for the surgical team.
OTTAVA is engineered for a wide range of **general surgical procedures**, including laparoscopic cholecystectomy, appendectomy, gastrectomy, gastric bypass, sleeve gastrectomy, fundoplication, hiatal hernia repair, splenectomy, small bowel resection, and lysis of adhesions. One of its key innovations is **Twin Motion™ technology**, which synchronizes movement of the operating table and robotic arms, allowing seamless patient repositioning and multi-quadrant access without undocking the robotic instruments. The system also incorporates advanced robotic instruments derived from Ethicon's extensive surgical expertise and connects to the **Polyphonic™ digital ecosystem** for workflow optimization, education, and data-driven surgical insights.
A major milestone was achieved in **July 2026**, when the **U.S. Food and Drug Administration (FDA)** granted **De Novo marketing authorization** for the OTTAVA Robotic Surgical System for multiple upper abdominal general surgery procedures. Johnson & Johnson has announced an initial commercial rollout in selected U.S. hospitals, with plans to expand indications and enter additional international markets. This approval positions OTTAVA as a significant competitor to existing robotic platforms such as the da Vinci Surgical System while introducing a novel, table-integrated approach to robotic surgery.